Actelion Drug Patent Portfolio
Actelion owns 6 orange book drugs protected by 18 US patents with Veletri having the least patent protection, holding only 2 patents. And Uptravi with maximum patent protection, holding 6 patents. Given below is the list of Actelion's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10821108 | Pharmaceutical composition containing 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsulfonyl)acetamide | 01 Dec, 2036 | Active |
| US10828298 | Pharmaceutical composition containing 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy]-N-(methylsulfonyl)acetamide | 01 Dec, 2036 | Active |
| US8791122 | Form-I crystal of 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsulfonyl)acetamide and method for producing the same | 01 Aug, 2030 | Active |
| US9284280 | Use of form-I crystal of 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsulfonyl)acetamide | 25 Jun, 2030 | Active |
| US9173881 | Therapeutic compositions containing macitentan | 12 Aug, 2029 | Active |
| US8268847 | Therapeutic compositions comprising a specific endothelin receptor antagonist and a PDE5 inhibitor | 18 Apr, 2029 | Active |
| US8367685 | Stable pharmaceutical compositions comprising a pyrimidine-sulfamide | 04 Oct, 2028 | Active |
| US7959945 | Dispersible bosentan tablet | 28 Dec, 2027 | Active |
| US9265762 | Stable pharmaceutical compositions comprising a pyrimidine-sulfamide | 29 May, 2027 | Active |
| US8318802 | Epoprostenol formulation and method of making thereof | 15 Mar, 2027 | Active |
| US8598227 | Epoprostenol formulation and method of making thereof | 02 Feb, 2027 | Active |
| US7205302 | Heterocyclic compound derivatives and medicines | 31 Oct, 2026 | Active |
| US10946015 | Stable pharmaceutical compositions comprising a pyrimidine-sulfamide | 11 Sep, 2026 | Active |
| US8309126 | Dispersible bosentan tablet | 15 May, 2026 | Active |
| US7094781 | Sulfamides and their use as endothelin receptor antagonists | 05 Dec, 2025 | Active |
| US5292740 | Sulfonamides | 20 Nov, 2015 | Expired |
| US5525616 | Method of inhibiting glycolipid synthesis | 11 Jun, 2013 | Expired |
| US5472969 | Method of inhibiting glycolipid synthesis | 13 May, 2013 | Expired |
Latest Legal Activities on Actelion's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Actelion.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 12th Year, Large Entity | 15 May, 2024 | US8318802 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 01 May, 2024 | US8309126 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 24 Apr, 2024 | US10828298 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 17 Apr, 2024 | US10821108 |
| Court Processing Terminated | 02 Apr, 2024 | US7205302 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 06 Mar, 2024 | US8268847 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 06 Mar, 2024 | US8268847 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 30 Aug, 2023 | US9284280 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 09 Aug, 2023 | US9265762 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 19 Apr, 2023 | US9173881 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 30 Nov, 2022 | US7959945 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 12 Jan, 2022 | US8791122 |
|
Patent Term Extension Certificate
Critical
| 12 Nov, 2021 | US7205302 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 19 May, 2021 | US8598227 |
|
Recordation of Patent Grant Mailed
Critical
| 16 Mar, 2021 | US10946015 |
Actelion Drug Patents' Oppositions Filed in EPO
Actelion drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Aug 11, 2016, by Generics (U.K.) Limited. This opposition was filed on patent number EP07763188A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
 | |||
| EP17186415A | Oct, 2020 | Generics [UK] Limited | Granted and Under Opposition |
| EP17191033A | Jul, 2020 | Stada-Arzneimittel Aktiengesellschaft | Granted and Under Opposition |
| EP17191033A | Jul, 2020 | Generics (UK) Ltd | Granted and Under Opposition |
| EP17191033A | Jul, 2020 | Aera A/S | Granted and Under Opposition |
| EP10792183A | Sep, 2018 | Hexal AG | Granted and Under Opposition |
| EP10792183A | Sep, 2018 | Generics [UK] Ltd | Granted and Under Opposition |
| EP10792183A | Sep, 2018 | Alfred E. Tiefenbacher (GmbH & Co. KG) | Granted and Under Opposition |
| EP09786912A | Jul, 2018 | Hexal AG | Granted and Under Opposition |
| EP09786912A | Jul, 2018 | Teva Pharmaceutical Industries Ltd | Granted and Under Opposition |
| EP09786912A | Jul, 2018 | STADA Arzneimittel AG | Granted and Under Opposition |
| EP09786912A | Jul, 2018 | Alfred E. Tiefenbacher (GmbH & Co. KG) | Granted and Under Opposition |
| EP09786912A | Jul, 2018 | Generics (UK) Ltd | Granted and Under Opposition |
| EP07763188A | Aug, 2016 | Generics (U.K.) Limited | Revoked |
Actelion's Family Patents
Actelion Drug List
Given below is the complete list of Actelion's drugs and the patents protecting them.
1. Opsumit
Opsumit is protected by 5 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8268847 | Therapeutic compositions comprising a specific endothelin receptor antagonist and a PDE5 inhibitor |
18 Apr, 2029
(3 years from now)
| Active |
| US8367685 | Stable pharmaceutical compositions comprising a pyrimidine-sulfamide |
04 Oct, 2028
(3 years from now)
| Active |
| US9265762 | Stable pharmaceutical compositions comprising a pyrimidine-sulfamide |
29 May, 2027
(1 year, 10 months from now)
| Active |
| US10946015 | Stable pharmaceutical compositions comprising a pyrimidine-sulfamide |
11 Sep, 2026
(1 year, 2 months from now)
| Active |
| US7094781 | Sulfamides and their use as endothelin receptor antagonists |
05 Dec, 2025
(5 months from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Opsumit's drug page
2. Opsynvi
Opsynvi is protected by 3 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8268847 | Therapeutic compositions comprising a specific endothelin receptor antagonist and a PDE5 inhibitor |
18 Apr, 2029
(3 years from now)
| Active |
| US10946015 | Stable pharmaceutical compositions comprising a pyrimidine-sulfamide |
11 Sep, 2026
(1 year, 2 months from now)
| Active |
| US7094781 | Sulfamides and their use as endothelin receptor antagonists |
05 Dec, 2025
(5 months from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Opsynvi's drug page
3. Tracleer
Tracleer is protected by 3 patents, out of which 1 has expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7959945 | Dispersible bosentan tablet |
28 Dec, 2027
(2 years from now)
| Active |
| US8309126 | Dispersible bosentan tablet |
15 May, 2026
(10 months from now)
| Active |
| US5292740 | Sulfonamides |
20 Nov, 2015
(9 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Tracleer's drug page
4. Uptravi
Uptravi is protected by 6 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10821108 | Pharmaceutical composition containing 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsulfonyl)acetamide |
01 Dec, 2036
(11 years from now)
| Active |
| US10828298 | Pharmaceutical composition containing 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy]-N-(methylsulfonyl)acetamide |
01 Dec, 2036
(11 years from now)
| Active |
| US8791122 | Form-I crystal of 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsulfonyl)acetamide and method for producing the same |
01 Aug, 2030
(5 years from now)
| Active |
| US9284280 | Use of form-I crystal of 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsulfonyl)acetamide |
25 Jun, 2030
(4 years from now)
| Active |
| US9173881 | Therapeutic compositions containing macitentan |
12 Aug, 2029
(4 years from now)
| Active |
| US7205302 | Heterocyclic compound derivatives and medicines |
31 Oct, 2026
(1 year, 3 months from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Uptravi's drug page
5. Veletri
Veletri is protected by 2 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8318802 | Epoprostenol formulation and method of making thereof |
15 Mar, 2027
(1 year, 8 months from now)
| Active |
| US8598227 | Epoprostenol formulation and method of making thereof |
02 Feb, 2027
(1 year, 7 months from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Veletri's drug page
Explore Our Curated Drug Screens
6. Zavesca
Zavesca is protected by 2 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US5525616 | Method of inhibiting glycolipid synthesis |
11 Jun, 2013
(12 years ago)
| Expired |
| US5472969 | Method of inhibiting glycolipid synthesis |
13 May, 2013
(12 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Zavesca's drug page